Compare RM & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RM | BWAY |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.4M | 337.9M |
| IPO Year | 2012 | 2019 |
| Metric | RM | BWAY |
|---|---|---|
| Price | $39.62 | $16.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $30.00 | $23.50 |
| AVG Volume (30 Days) | 59.1K | ★ 59.5K |
| Earning Date | 02-04-2026 | 11-11-2025 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | 71.26 | ★ 213.09 |
| EPS | ★ 4.13 | 0.13 |
| Revenue | ★ $610,145,000.00 | $49,094,000.00 |
| Revenue This Year | $16.34 | $330.76 |
| Revenue Next Year | $7.05 | $22.24 |
| P/E Ratio | ★ $9.70 | $52.44 |
| Revenue Growth | 9.60 | ★ 27.08 |
| 52 Week Low | $25.41 | $7.84 |
| 52 Week High | $46.00 | $18.18 |
| Indicator | RM | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 58.29 | 55.03 |
| Support Level | $35.99 | $16.75 |
| Resistance Level | $40.40 | $18.18 |
| Average True Range (ATR) | 1.40 | 0.74 |
| MACD | 0.39 | 0.05 |
| Stochastic Oscillator | 83.03 | 70.49 |
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.